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Adoptively transferred cells immune to tumor-associated antigens have often been 
studied  as  a  potential  approach  to  experimental  tumor  therapy  in  animals  (1). 
Although the lymphoid cells used have been largely derived by immunization in vivo, 
attempts  have  been  made  to  enhance  the  therapeutic  efficacy of immune  cells by 
using techniques  for secondary sensitization to tumor in vitro (2-6).  The purpose of 
secondary sensitization in vitro of cells primed in vivo is to bypass mechanisms that 
limit effective sensitization in vivo and thus increase the quantity of effector cells (7- 
9). 
The  utility of in  vitro  sensitization  has  been  limited  by  inefficient expansion  of 
effector  cells  (10),  in  part  because  of  progressive  cell  loss  during  culture  (3,  4). 
However, culture with interleukin 2 (IL-2) 1 can potentially overcome these problems. 
Activated T  lymphocytes can  be induced  to proliferate and  expand  numerically in 
vitro  by  IL-2  and  can  be  maintained  continuously,  even  without  the  continued 
presence of the activating antigen (11-15). By repeatedly supplementing cultures with 
IL-2, lymphocytes cytotoxic to tumors can be grown in vitro to large numbers (12,  16, 
17). 
We recently examined the efficacy of such long-term cultured T  lymphocytes in the 
adoptive therapy of FBL-3, a syngeneic transplantable Friend virus-induced leukemia. 
In  the  model  used,  denoted  as adoptive chemoimmunotherapy,  advanced  dissemi- 
nated  tumor  can  be  successfully treated  with  a  combination  of cyclophosphamide 
(CY)  plus cells from immune mice  (18).  The CY has a  direct tumoricidal effect  (18) 
as  well  as  a  potential  facilitating  role  on  host  tumor  immunity  (19),  and  the 
therapeutic efficacy of donor cells is mediated by specifically immune T  lymphocytes 
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(20,  21).  In prior studies, donor lymphocytes were derived from mice immunized  to 
FBL-3 and tested directly in therapy without  culture  (18).  Recently, similar in vivo 
immunized cells have been cultured long-term with IL-2 after specific activation by 
secondary  sensitization  to  FBL-3  in  vitro  and  have  been  shown  to  be  specifically 
cytotoxic to FBL-3 and able to mediate specific adoptive chemoimmunotherapy (21). 
Such long-term cultured T  lymphocytes are exquisitely dependent upon repeated 
exposure to exogenous IL-2 in vitro for both proliferation and survival in vitro (14). 
The current studies were performed to determine whether the in vivo efficacy of long- 
term cultured T  lymphocytes might also be augmented by exogenously administered 
IL-2. The results demonstrated  that although  IL-2 had no detectable intrinsic anti- 
tumor activity when used alone or with CY, it significantly enhanced the therapeutic 
efficacy of long-term cultured T  lymphocytes in adoptive chemoimmunotherapy. 
Materials  and  Methods 
Mice.  8- to  12-wk-old C57BL/6  mice were obtained from Simonsen Laboratory, Gilroy, 
CA. 
Tumor.  FBL-3 is a  transplanted ascitie Friend virus-induced leukemia of C57BL/6 origin 
that possesses  tumor-associated surface antigens that cross-react with other FMR tumors (22, 
23). 
Preparation of Concanavalin A  (Con A )-stimulated Cell Supernatants.  Conditions for the prepara- 
tion of Con A supernatants used for cell culture were similar to those of Lafferty et al. (24) and 
have been  previously described (21).  Spleen cells from  6- to  12-wk-old BALB/c mice were 
removed~sPOOled  , minced, forced through stainless steel mesh, and brought up to a concentration 
of 1 ×  10  cells/ml in RPMI supplemented with Hepes, 2-mercaptoethanol, glutamine, sodium 
pyruvate, nonessential amino acids, antibiotics, and Con A at a concentration of 5 #g/ml. 3 ml 
of this cell suspension was incubated in a horizontal 75-cm  ~ flask at 37 °C for 2 h, which allowed 
the formation of a cell monolayer. The monolayers, washed three times to remove excess Con 
A  and nonadherent  cells, were incubated at 37°C  for  18 h  with 30 ml of the supplemented 
serum-free  media.  After  incubation,  the  supernatants  were  decanted,  centrifuged,  passed 
through  an  0.5-#m  Nalgene  filter, dialyzed, concentrated  10-fold, resterilized by  millipore 
filtration, and stored at  15°C. 
Preparation of Purified IL-2.  IL-2 for in vivo therapy was derived from a  radiation-induced 
murine splenic T  cell lymphoma denoted as LBRM (26). IL-2 from cultured LBRM cells was 
purified biochemically as detailed elsewhere (25). The cells were cloned by a limiting dilution 
procedure, and the work described here used LBRM clone 5A4. To produce IL-2 for purigca- 
tion, LBRM cells were seeded in Falcon T75  tissue culture flasks (Falcon Labware, Div. of 
Becton, Dickinson & Co., Oxnard, CA) in medium supplemented with  10% fetal calf serum 
(FCS) and were grown to confluency. Culture medium was removed and replaced with serum- 
free medium containing 1% phytohemagglutinin (Gibco Laboratories, Grand Island Biological 
Company, Grand Island, NY) for 20 h. Culture supernatants were then removed, and the cells 
were removed by centrifugation at  10,000 g for  15 rain. The resulting supernatant was then 
concentrated by ammonium sulfate precipitation. 
For biochemical purification of IL-2, all chromatography was performed at 4°C by using 
sterile buffers. Concentrated supernatants containing IL-2 activity were dialyzed against 0.04 
M  NaCI-Hepes buffer (pH  7.2)  and then fractionated by using DEAE-Sephacel, as detailed 
elsewhere (27,  28).  The  ionic strength of the fractions collected was determined by using a 
conductivity meter and then assayed for activity. Column fractions containing biologic activity 
were pooled and fractionated by gel filtration by using a  2- ×  90-era column of AcA54 (LKB 
Produkter, Sweden) equilibrated in 0.9% saline, as detailed elsewhere (27, 28). 
Flat-bed isoelectric focusing  (IEF)  was  performed  in  horizontal layers of Sephadex  (27). 
Samples were prepared in  100 ml solution containing 1% glycine, 0.1% aspartic acid, and 2% 
amphylines (pH 3-10; LKB Produkter, Sweden). The sample was mixed with 5 gm Ultradex 
(LKB Produkter), and the gel suspension was spread in a gel tray. The tray was electrophoresed 
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increased from  100  to  1,000 volts  (27). After electrophoresis,  the  gel  was  sectioned into 30 
portions, and the pH  and IL-2 activity in each was  determined. After flat-bed IEF, active 
fractions were pooled, concentrated by lyophilization  and electrophoresis on a preparative slab, 
mono-Tris biline sodium dodecyl sulfate (SDS)-polyacrylamide gel system (29). Electrophoretic 
elution of a stained protein band (Rf corresponding to 26,000 m/~) yielded purified IL-2 used 
in these studies. 
Before  use in in vivo trials, electro-elated IL-2 was  diluted to  a  concentration of  100  U 
IL-2/ml in 0.9% NaCI containing 1 /~g/ml  polyethylene glycol  to  aid  in protection of the 
molecule during subsequent in vitro manipulation associated with injection. 
Purified IL-2 has no interferon, macrophage/granulocyte colony-stimulating  factor, interleu- 
kin 1, or burst promoting activity (30). 
Assay for IL-2 Activity.  The amount of IL-2 activity present in supernatant samples was 
determined in a  standard microassay  (14) based  upon the  IL-2-dependent proliferation of 
CTLL-2, a cytotoxic T cell line (12). Briefly, CTLL cells were cultured in 200-/~1 volumes in fiat 
bottomed microplate wells in Clicks medium (Altick Associates,  Hudson, WI) supplemented 
with  10%  FCS,  300 /~g/ml  L-glutamine, 25  mM  Hepes  buffer,  16  mM  NaHCOa,  50  U/ml 
penicillin, and 50/~g/ml streptomycin. Each well contained 4,000 CTLL cells together with a 
log2 dilution (ranging from 0.1 to 50% by volume) of a putative IL-2-containing  sample. After 
a 24-h incubation (37°C in a humidified atmosphere of 5% COz and air) the microplate wells 
were pulsed with 0.5 Ci of [3H]thymidine. Cultures were  harvested 4 h  later onto glass fiber 
filter strips, and [ZH]thymidine incorporation was determined via liquid scintillation. Results 
were quantified by probit analysis (14). IL-2 activity was expressed in units per ml by comparing 
experimental probit data with that obtained from assay of a standard IL-2 sample assigned a 
value of 1 U/ml (48-h tissue culture medium conditioned by the 5 ~g/ml Con A stimulation of 
rat splenocytes (106 cells/ml)). 
In Vivo Immunization of Donor Mice to Tumor.  C57BL/6 mice were immunized by two weekly 
inoculations of 2 ×  10  FBL-3 irradiated with  10,000 rad. 6 wk after the second inoculation, 
spleen cells were  removed and teased to form single cell  suspensions. Viable nucleated cells 
were enumerated by trypan blue dye exclusion. 
Generation  of  Specifically  Cytotoxic Long-Term Cultured  T  Lymphocytes for  Adoptive Therapy. 
Lymphocytes from spleens of mice previously immunized to FBL-3, denoted as C57,FBL, were 
specifically activated by culture for  7 d  with  tumor and then nonspecifically expanded in 
number by subsequent culture with Con A supernatants containing IL-2 under conditions 
previously described (21). 60 X 106 stimulator cells (C57,FB0 were cultured for 7 d with 3 ×  106 
irradiated FBL-3 cells, (FBL)x, in 20 ml of RPMI supplemented with FCS, 2-mercaptoethanol, 
and antibiotics, at  37°C in 5%  CO2 humidified atmosphere.  By using simultaneous culture 
with a non-cross-reactive  syngeneic tumor, EL-4(G-), and by serially examining  culture cells for 
cytolytic reactivity in a standard 4-h chromium release assay, we previously demonstrated (21) 
that such secondary sensitization in vitro results in specific activation of tumor-specific cytotoxic 
cells. 
After 7 d ofcuhure, cells were washed, pooled, and reestablished in culture at a concentration 
of 1.5 ×  105 cells/ml, under culture conditions as described above, but with the addition to 
media of concentrated Con A-stimulated cell supernatants at a  I: 10 volume ratio. On day  10 
and  day  16  of culture,  8  ml  of media was  removed  and  replaced  with  fresh  media at  a 
concentration of  1.5  ×  10  ~ cells/ml. On  day  19,  ceils  were  harvested,  washed,  and  viable 
nucleated cells enumerated. 
Such long-term cultured lymphocytes were  expanded in number to -700% and remained 
specifically cytotoxic to FBL-3.  They were exquisitely dependent upon the presence of IL-2. 
Continued growth required repeated addition of supernatant from Con A-stimulated lympho- 
cytes containing IL-2. Cells cultured without IL-2 supplementation died rapidly. 
In  Vivo Adoptive Chemoimmunotherapy Model  The assay  for  treating advanced disseminated 
FBL-3 with a combination of nonlethal, noncurative chemotherapy and adoptively transferred 
immune cells has previously been described (18, 20, 21). C57BL/6 mice inoculated with 5 X 
10  ~ FBL-3 on day 0 are treated on day 5. Treatment with CY prolongs the median survival 
time (MST) to ~4 wk but cures no mice. Therapy with immune cells alone on day 5 without 
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cells from mice immunized with FBL-3 or with similar cells after sequential activation in vitro 
and nonspecific expansion by culture with IL-2 prolongs survival and cures mice, depending on 
the dose of cells administered  (21).  Mice surviving to day 80 were considered cured because 
relapses  are  very  rare  after day  80.  The  specificity of adoptive chemoimmunotherapy  with 
either  noncultured  or  cultured  immune  cells  has  been  confirmed  in  reciprocal  specificity 
experiments  (20,  21)  using  the  adoptive  chemoimmunotherapy  of an  antigenically  distinct 
chemically induced tumor, EL-4(G-), in criss-cross therapy experiments. 
Statistical  Analysis.  Survival curves were derived  from cumulative experiments, with each 
data point representing the percentage of mice surviving on that day. The significance of the 
observed differences in survival times between groups was determined by a  rank test designed 
for the analysis of multiple samples with censored observations (31).  Two sample differences 
were confirmed using a  generalized Wilcoxon test (32). 
Results 
To determine whether exogenously administered IL-2 could enhance the therapeu- 
tic efficacy of long-term cultured T  lymphocytes in  adoptive tumor therapy, mice 
bearing disseminated FBL-3 were treated with CY and long-term cultured T  lym- 
phocytes plus purified IL-2. Cells for therapy were derived from cultures of spleen 
cells obtained from C57BL/6 mice immunized in vivo with FBL-3, activated in vitro 
by culture for 7 d  with irradiated FBL-3, and nonspecifically expanded in vitro to 
day 19 by repeated exposure to partially purified supernatants from Con A-stimulated 
lymphocytes containing IL-2. These long-term cultured T  lymphocytes, denoted as 
C57,,FBL (cultured), were highly cytotoxic to FBL-3, but not EL-4(G-), an antigenically 
distinct C57BL tumor (Table I). Recipient specificity of cytotoxicity has previously 
been confirmed (21). 
C57,~FBL (cultured)  continue to proliferate in  vitro and expand in number when 
repeatedly exposed  to  IL-2 in  vitro.  However, when cultured without IL-2, <10% 
remains  viable  at  72  h.  When  the  proliferative capacity of C57,~vaL (cultured)  is 
TABLE  I 
Effect of y #radiation  on the Cytolytic Reactivity of Long-Term  Cultured T 
Lymphocytes* 
Radiation dose to 
cytotoxic effector 
cells 
Percent specific lysis 
FBL-3  EL-4(G-) 
20:1  5:1  20:1  5:1 
rad 
0  85  74 
300  88  7l 
1,200  83  67 
4,800  62  34 
9,600  29  12 
17  15 
* Spleen cells  from  C57BL/6  mice that had  been  immunized in  vivo with 
FBL-3 were cultured for 7 d with irradiated FBL-3 and then further cultured 
to day 19 in media supplemented with IL-2. Cytotoxicity against FBL-3 and 
EL-4(G-)  was  determined on  day  19  in a  4-h chromium  release assay at 
effector-to-target ratios of 20:1  and 5:1.  Effector cells were irradiated with 
variable doses  at a  rate of 230  rad/min with a  137CSC1 gamma  irradiator 
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inhibited  by  y  irradiation  with  1,200  rad,  >95%  of cells  die  within  72  h,  despite 
culture with IL-2. 
Before examining the in vivo effects of exogenous IL-2 on adoptively transferred 
long-term cultured T  lymphocytes, the radiation sensitivity of long-term cultured T 
lymphocytes was determined both in vitro and in vivo to establish a potential role for 
donor cell proliferation in vivo. C57,FBL (cultured) were treated with variable doses 
of y  irradiation and  tested for cytolytic reactivity in  a  4-h chromium release assay 
(Table I) and for efficacy in tumor therapy (Fig. 1). Cytolytic reactivity of long-term 
cultured T  lymphocytes was inversely related to the dose of radiation. However, at a 
dose of 1,200 rad, which significantly inhibited cell proliferation, C57~rm~ (cultured) 
remained highly cytotoxic to FBL-3. To determine whether cytotoxic effector cells 
must be capable of proliferating to be effective in vivo, mice were treated with CY 
plus C57,FBL  (cultured)  that  had been irradiated with  1,200  rad,  and  results were 
compared to therapy with CY and nonirradiated C57~rBL (cultured). 
The cumulative  data of two  therapy experiments are  presented in  Fig.  1.  Mice 
inoculated with 5 X  106 FBL-3 on day 0 and given no treatment had an MST of 11 
d, and all died by day 16. Therapy on day 5 with CY alone (180 mg/kg) prolonged 
the  MST  to  day  24.  As  an  adjunct  to  CY,  therapy  with  nonirradiated  C57,FBL 
(cultured) had a significant dose-dependent effect on survival. Thus, 2.5 ×  106 C57~Fm. 
(cultured)  prolonged the  MST  to  day  38  (P <  0.01),  5  X  106 C57~FBI. (cultured) 
prolonged the MST to day 49, and  10 X  106 C57,FBL  (cultured)  further prolonged 
survival and cured 11 of 16 mice. In contrast, therapy with CY plus 5 X  106 irradiated 
C57~FBL (cultured) prolonged the MST to only day 30 and thus was significantly (P 
<  0.01) more effective than therapy with CY alone but less effective (P <  0.01) than 
therapy with one-half the dose of nonirradiated cells. These findings are consistent 
with the assumption that the ability of long-term cultured T lymphocytes to proliferate 
in  vivo is  not  an  absolute requirement  for efficacy in  therapy but  is  necessary for 
optimum therapeutic benefit and  imply that  the  therapeutic efficacy of long-term 
cultured T  lymphocytes might be augmented if the in vivo proliferation of such cells 
was enhanced or prolonged by exogenous IL-2. 
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Fro.  1.  Efficacy of irradiated long-term cultured T  lymphocytes in adoptive chemoimmunotherapy 
of FBL-3. C57BL/6 mice inoculated intraperitoneally with 5 X  10  n FBL-3 on day 0 received either 
no therapy (no Tx), treatment on day 5 with cyclophosphamide (CY alone) at a dose of 180 mg/kg, 
or therapy with CY plus variable doses of spleen cells from mice immunized in vivo with FBL-3, 
and subsequently secondarily sensitized in vitro and numerically expanded by culture through day 
19  with  IL-2,  denoted  as  CY  +  CI57~FBL (cultured).  Cells were  tested  directly  from culture  or 
immediately after  1,200  rad irradiation. The cumulative data from two experiments are presented. M.  A.  CEtEEVER,  P.  D.  GREENBERG,  A.  FEFER,  AND S.  GILLIS  973 
The cumulative data of two therapy experiments examining the in vivo efficacy of 
purified IL-2 are presented  in Fig.  2.  Mice inoculated with 5  ×  106 FBL-3 on day 0 
and given no treatment had an MST of 11 d. Treatment  with IL-2 alone, 80 U/d, on 
days 5-9, had no effect on survival. Therapy on day 5 with CY alone (180 mg/kg) or 
with  CY  plus  II-2 on  days  5-9  prolonged  the  MST  to day  24.  Thus,  IL-2 had  no 
detectable anti-tumor effect either by itself or as an adjunct to CY. 
Therapy on day 5 with CY plus 5 X  106 C57,FnL (cultured)  further prolonged the 
MST to day 38, but no mice were cured. In contrast, therapy on day 5 with CY and 
5  X  106 C57,FBL  (cultured)  plus  80  U/d  of IL-2 on days 5-9 cured  11  of 16  mice. 
Thus, as an adjunct to CY, long-term cultured T  lymphocytes were effective in tumor 
therapy, and their efficacy was significantly (P <  0.01)  augmented by inoculation of 
exogenous IL-2. 
Because exogenous IL-2 promotes continued proliferation  and prolonged survival 
of long-term  cultured  T  lymphocytes  in  vitro,  exogenous  IL-2  may  augment  the 
therapeutic  efficacy  of such  cells  by  performing  a  similar  function  in  vivo.  This 
mechanism  has  not  yet  been  established  by  quantitating  in  vivo  proliferation  of 
cultured cells in response to IL-2. However, if exogenously administered IL-2 augments 
the in vivo therapeutic  efficacy of long-term cultured cells by stimulating continued 
clonal expansion in vivo, then the efficacy of IL-2 should be abolished by irradiating 
donor cells to prevent  further proliferation.  Thus, the ability of IL-2 to augment the 
therapeutic  efficacy of irradiated  C57aFBL  (cultured)  was  examined ,(Fig.  3).  Mice 
inoculated with FBL-3 on day 0 and given no treatment all died by day 13. Treatment 
with CY alone prolonged the MST to day 24, Therapy with CY plus 5 ×  106 C57,~FBL 
(cultured),  which had been y  irradiated  with  1,200 rad immediately before therapy, 
prolonged the  MST  to day 29,  whereas  therapy  with  CY and  an equal  number of 
irradiated  C57~FBL  (cultured)  plus  IL-2 prolonged the  MST  to day 31  but  was  not 
significantly  different  (P  -  0.56).  By  contrast,  therapy  with  CY  and  5  ×  106 
nonirradiated  C57,FBL  (cultured)  prolonged  MST  to day 38, and  therapy with CY 
and 5  X  106 nonirradiated  C57,FBL (cultured)  plus IL-2 prolonged the MST to day 
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Fro.  2.  Efficacy  of purified IL-2 in vivo as an adjunct to long-term cultured T lymphocytes in 
adoptive chemoimmunotherapy. C57BL/6 mice inoculated intraperitoneally with 5 ×  106 FBL-3 
on day 0 received either no therapy  [no Tx], treatment  on days 5-9 with IL-2, 80 U/day (IL-2 
alone), treatment on day 5 with cyclophosphamide at a dose of 180 mg/kg (CY alone), treatment 
with CY on day 5 plus IL-2 on days 5-9 (CY + IL-2), treatment on day 5 with CY and 5 X 106 
long-term cultured T lymphocytes immune to FBL-3 (CY + C57~FBL [cultured]), or treatment  on 
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FtG.  3.  Efficacy  of purified IL-2 as an adjunct to irradiated long-term cultured T lymphocytes  in 
adoptive chemoimmunotherapy of FBL-3. C57BL/6 mice inoculated on day 0 with FBL-3 received 
either no therapy (no Tx), treatment on day 5 with cyclophosphamide (CY alone), treatment on 
day 5 with CY plus nonirradiated long-term cultured T lymphocytes immune to FBL-3 (CY + 
C57=FBL (cultured)), treatment on day 5 with CY and C57~FBL (cultured) plus IL-2 on days 5-9 (CY 
+ C57=~'BL [cultured] + IL 2), treatment on day 5 with CY and C57,FBL (cultured) that had been 
irradiated  with  1,200 rad  immediately before therapy  (CY  +  irradiated C57~FBL[cuhured]), or 
treatment with CY and irradiated C57~rBL (cultured) on day 5 plus IL-2 on days 5-9 (CY + 
irradiated C57~FBC [cultured] + IL-2). 
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FIG. 4.  Efficacy  of purified IL-2 as an adjunct to noncuhured immune cells in adoptive chemoim- 
munotherapy of FBL-3. C57BL/6 mice inoculated with FBL-3 on day 0 received either no therapy 
(no Tx), treatment on day 5 with cyclophosphamide (CY alone), treatment on day 5 with CY and 
noncultured immune cells (CY +  C57,FBL [noncuhured]), or treatment on day 5 with CY and 
C57,,FBL (noncultured) plus IL-2 on days 5-9 (CY +  C57,FBL [noncuhured] +  ]L-2). Fractions 
represent the number of mice surviving in the total cumulative group of two experiments. 
exogenous IL-2 in adoptive chemoimmunotherapy required that  the effector cell be 
capable of proliferating in the host. 
In the preceding experiments, cells from mice immunized in vivo were grown in 
vitro by culture with IL-2 and then used for tumor therapy. These long-term cultured 
cells were exquisitely dependent upon IL-2 for survival in vitro, and their efficacy in 
vivo was augmented by exogenous IL-2. We subsequently examined whether exoge- 
nously  administered  IL-2  could  augment  the  therapeutic  efficacy  of  adoptively 
transferred noncultured donor lymphocytes that were specifically immune to tumor 
but  not  immediately  dependent  on  exogenous  IL-2  for  survival  (Fig.  4).  Mice 
inoculated with 5 X  106 FBL-3 on day 0 and not treated died by day 16. Therapy on 
day 5 with CY alone prolonged the MST to day 24. Therapy with CY plus 5  X  106 
noncultured immune spleen cells, denoted as C57~BL  (noncultured), prolonged the 
MST to day 30 and cured 5 of 32 mice (P <  0.01).  Therapy with CY plus 5  X  106 
C57~FBL (noncultured) plus 80 U/d of IL-2 on days 5-9 similarly prolonged the MST M.  A.  CHEEVER,  P.  D.  GREENBERG,  A.  FEFER, AND  S.  GILLIS  975 
to day 30 and cured  1 of 16 mice. Thus, although noncultured immune cells were 
effective in tumor therapy, their efficacy was not augmented by exogenous IL-2. 
Discussion 
Both noncultured immune cells and  long-term cultured immune T  lymphocytes 
are capable of mediating specific adoptive tumor therapy. At the time that they are 
used  for  therapy,  noncultured  immune  cells  are  not  a  rapidly  proliferating  cell 
population  (33)  and are not directly cytotoxic to tumor  (4).  In contrast, long-term 
cultured T  lymphocytes are rapidly proliferating and are directly cytolytic to tumor. 
Noncultured immune cells must be capable of proliferation in the host to be effective 
in therapy and must survive in the host for a minimum of 2 wk for maximum efficacy 
in therapy (34).  Long-term cultured T  lymphocytes are capable of lysing tumors at 
the time of therapy;  thus,  their ability to function in therapy need not  necessarily 
require either  further  proliferation in  the  host  or  prolonged  survival  in  the  host. 
However, because  their therapeutic efficacy is  cell-dose dependent,  any  technique 
that induces numerical expansion of donor cells in vivo should augment their efficacy 
in vivo. Because the ability of long-term cultured ceils to proliferate and survive, at 
least  in  vitro, is  exquisitely dependent  upon  repeated exposure to exogenous IL-2, 
their ability to proliferate and survive in vivo, and thus their effectiveness in therapy, 
is  likely to be dependent  upon  the  availability of either endogenous or exogenous 
IL-2. 
The in vivo distribution and availability of endogenous IL-2 is unknown because 
it is not  readily detectable in serum by bioassay, and no radioimmunoassay for its 
presence has been reported. However, because the availability of endogenous IL-2 
might limit the therapeutic efficacy of adoptively transferred long-term cultured T 
lymphocytes, the current studies were performed to determine whether exogenously 
administered IL-2 could augment the in vivo efficacy of such long-term cultured T 
lymphocytes. The results demonstrated that although IL-2 had no detectable intrinsic 
anti-tumor  activity  when  used  alone  or  with  CY,  it  significantly  augmented  the 
therapeutic efficacy of long-term cultured T  lymphocytes in adoptive chemoimmu- 
notherapy. 
In the present studies, supernatants from Con A-stimulated mouse spleen cells that 
had been only partially purified were used for cell culture in vitro, and purified IL-2 
was used  for therapy in vivo. Con A  supernatants  contain not only IL-2 but other 
lymphokines and  monokines, such  as colony-stimulating factors, interleukin  1 and 
immune interferon, as well as cell breakdown products and small amounts of residual 
lectin (24).  Because the end point of culture was the growth of activated T  lympho- 
cytes, and because Con A supernatants supported growth well, the presence of these 
impurities was acceptable. However, such crude supernatants  are inappropriate for 
testing the effect of IL-2  in  vivo because  the  presence of impurities  would  render 
results uninterpretable. In fact, in preliminary experiments, partially purified Con A 
supernatants had a small direct anti-tumor effect in therapy. Thus, to determine the 
pharmacological anti-tumor effect of IL-2 in  vivo, we used  purified IL-2 that  had 
been  produced  by the  lymphoma cell line  LBRM  (26)  and  isolated by successive 
ammonium sulfate precipitation, gel exclusion chromotography (G-100), ion exchange 
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resis (electroelution). This preparation migrates as a single band upon secondary SDS- 
poly acrylamide gel electrophoresis and contains no known functional activity other 
than  those postulated  to be associated with  IL-2. It has been functionally screened 
and  is  negative  for  interferon,  colony-stimulating  factor,  interleukin  1,  and  burst- 
promoting activity (30). 
The mechanism by which  IL-2 functions  in vivo to augment the efficacy of long- 
term cultured T  cells has not yet been established.  However, mechanisms extraneous 
to, or independent of, the intrinsic functional properties of IL-2 were rendered unlikely 
by the use of purified IL-2. Because the effector cell for therapy is a  T  lymphocyte 
and because IL-2 provides for T  cell growth in vitro, it is likely that exogenous IL-2 
promotes in vivo growth of adoptively transferred cultured cells. This assumption is 
supported  by  the  finding  that  ILo2  does  not  enhance  the  therapeutic  efficacy  of 
irradiated long-term cultured cells that are cytotoxic in vitro to tumor and modestly 
effective in therapy in vivo but that are incapable of further proliferation in the host. 
These  data,  however,  do  not  rule  out  the  possibility  that  radiation  of donor  cells 
inhibits  a  donor cell function  vital to therapy other than  the  ability to proliferate, 
such  as  the  ability  to  home  to  sites  of tumor or the  ability  to  survive  in  the  host 
independent of the ability to proliferate. Thus, the final proof of donor cell growth in 
vivo in response to IL-2 will require actual quantitation of either donor cells or donor 
cell divisions in vivo. 
Exogenous IL-2 augmented the in vivo efficacy of long-term cultured T lymphocytes 
but not the efficacy of noncultured immune cells. Augmentation of long-term cultured 
cells might simply reflect an exquisite dependence upon IL-2 for survival. Although 
the reasons  for the inability of IL-2 to augment  the in  vivo efficacy of noncuhured 
immune cells have not been determined, they may relate to multiple factors, such as 
donor cell subtype, the time of IL-2 administration, or the presence of serum inhibitors 
to IL-2 function after therapy with noncultured spleen cells but not long-term cultured 
T  lymphocytes. 
The  predominant  cell  responsible  for  the  therapeutic  efficacy  of  noncultured 
immune cells is an immune Lyt 1+2 - T  cell that is not cytotoxic at the time of therapy 
(35).  The mechanism by which these cells promote in vivo eradication of established 
FBL-3  is  unknown  but  must  reflect  one  or  several  of  the  T  effector  functions 
characterized  by the subset--helper cells for antibody responses,  initiators  of DTH 
responses,  and  amplifiers  of  CTL  responses.  The  inability  of exogenous  IL-2  to 
augment  the efficacy of noncultured  immune cells does not  further define which of 
these mechanisms are operative. Helper cells for antibody responses and initiators of 
DTH responses grow in conditioned media containing IL-2 (36,  37).  Although  there 
is no evidence that  amplifiers of CTL responses grow in  response to  IL-2, the cells 
that  they amplify grow in response to IL-2. Thus, exogenous IL-2 could potentially 
augment the efficacy of any of these cell populations. 
The inability of exogenous IL-2 to augment noncultured immune cells might reflect 
timing of IL-2 administration rather than donor T  cell subtype. As an example, if the 
critical  immune cell  for adoptive chemoimmunotherapy of established  tumor is  an 
amplifier ofcytotoxic cells, one might expect that tumor eradication would be delayed 
for a  period of time after adoptive transfer (34), during which time expansion of the 
pool  of cytotoxic  effector cells  may  occur.  During  the  early  phase  after  therapy, 
endogenous  IL-2  or  IL-2  produced  by  donor  cells  might  be  sufficient  to  support M.  A.  CHEEVER,  P.  D.  GREENBERG,  A.  FEFER,  AND  S.  GILLIS  977 
maximum in vivo clonal expansion of anti-tumor CTL, and exogenous IL-2 would be 
ineffective. However, during the  latter phase after therapy, after significant clonal 
expansion of cytotoxic cells occurred in vivo, endogenous or donor cell IL-2 might be 
deficient  in  relationship  to  the  expanded  numbers  of cytotoxic cells  bearing  IL-2 
receptors or even  depleted  by such  cells  (38),  and  exogenous IL-2  might  then  be 
effective~ This possibility has not yet been tested. 
Another reason might be the presence of inhibitors to IL-2 functioning in the sera 
of mice after therapy with CY and  noncultured immune spleen ceils but  not after 
therapy with CY and long-term cultured T  lymphocytes. Sera of normal mice contain 
high  levels  of an  inhibitor  to  IL-2  that  is  induced  by  Lyt  23  +  cells  but  that  is 
dramatically decreased by moderate doses of CY  (39).  Thus, in our models, serum 
inhibition to IL-2 activity is presumably low after therapy with CY alone. However, 
if noncultured  immune  spleen cells are  capable of reconstituting CY-treated  mice 
with  inhibitor-inducing cells,  normal  or increasing levels of IL-2 inhibitor activity 
might be present at the time of IL-2 administration. By contrast, if long-term cultured 
immune cells contain no such normal inhibitor-inducing cells, serum inhibitor activity 
at the time of IL-2 administration would be low. 
Recently, it has been demonstrated that  in vivo inoculation of partially purified 
supernatants from Con A-stimulated spleen cells containing IL-2 can restore cytotoxic 
T  cell responsiveness in athymic nu/nu mice (40)  and augment in vivo generation of 
cytotoxic T  cells to TNP-modified cells in the draining lymph node of normal mice 
(41). Although the level of reactivity in those experiments was extremely low and the 
IL-2 was not purified, the results suggested a potential in vivo role for IL-2 and offered 
the hope that  IL-2 could be used to augment T  cell-mediated tumor therapy. The 
current  studies  confirmed this  possibility by demonstrating  that  purified IL-2 can 
augment  donor T  cell immunity  in  vivo after therapy with  long-term cultured  T 
lymphocytes.  Although  exogenous  IL-2  was  unable  to  augment  the  therapeutic 
efficacy of noncultured immune ceils under the conditions tested, further examination 
of these models to determine the mechanisms responsible for allowing and/or disal- 
lowing exogenous IL-2 to function in vivo might offer the possibility that pharmaco- 
logic IL-2 can be used to control other T  cell reactions in vivo. 
Summary 
Spleen cells from C57BL/6 mice immunized in vivo with a syngeneic Friend virus- 
induced leukemia, FBL-3, were specifically activated by culture for 7 d with FBL-3, 
then nonspecifically induced to proliferate in vitro for 12 d by addition ofsupernatants 
from concanavalin A-stimulated lymphocytes containing interleukin 2  (IL-2). Such 
long-term cultured  T  lymphocytes have previously been shown  to specifically lyse 
FBL-3 and  to mediate specific adoptive therapy of advanced  disseminated  FBL-3 
when used as an adjunct to cyclophosphamide (CY) in adoptive chemoimmunother- 
apy. Because the cultured cells are dependent upon IL-2 for proliferation and survival 
in vitro, their efficacy in vivo is potentially limited by the availability of endogenous 
IL-2.  Thus,  the  aim  of the  current  study  was  to  determine  whether  exogenously 
administered purified IL-2 could augment the in vivo efficacy of long-term cultured 
T  lymphocytes. 
Purified  IL-2  alone  or  as  an  adjunct  to  CY  was  ineffective in  tumor  therapy. 
However, IL-2 was extremely effective in augmenting the efficacy of IL-2-dependent 978  TltERAPY WITtt LONG-TERM  CULTURED  CELI,S AND  INTERLEUKIN  2 
long-term cultured T  iymphocytes in adoptive chemoimmunotherapy. The  mecha- 
nism by which  IL-2  functions in vivo is presumably by promoting in vivo growth 
and/or survival of adoptively transferred cells. This assumption was supported by the 
findings that IL-2 did not enhance the modest therapeutic efficacy of irradiated long- 
term cultured cells that were incapable of proliferating in the host and was ineffective 
in augmenting the in vivo efficacy of noncultured immune cells that are not imme- 
diately dependent upon exogenous IL-2 for survival. 
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